This atlas is a superb guide to the use of PET-CT for the evaluation of treatment response in oncology patients based on its ability to assess tumor metabolic status. The first part of the book explains the role of PET-CT in response evaluation in different treatment settings. For comparison, overviews of the value and limitations of CT alone, PET alone, and anatomical and functional MRI are included. Guidance is also provided on the reporting of PET-CT scans in post-therapy scenarios. The second part of the book describes and illustrates the use of PET-CT with FDG and other tracers to assess the treatment response of malignancies at different anatomic sites. Featuring a wealth of images, informative case-based discussion, and evidence-based teaching points, these disease-specific chapters clearly demonstrate the key role that PET-CT can play in distinguishing early responders from patients who are non-responders or are resistant to treatment. Prompt and accurate evaluation of treatment response is vital as we enter the era of individualized medicine, and this atlas will persuade readers of the considerable advantages of PET-CT over conventional radiological and clinical methods.

<p>PART I General Chapters: Introduction to Treatment response evaluation:  Science and Practice

CT in Treatment response evaluation - Overview
MRI & Diffusion weighted MRI in Treatment response evaluation- Overview
PET & PET-CT in Treatment response evaluation-Overview
Conventional Radiological Techniques and PET-CT in Treatment response evaluation in post-surgical setting
Conventional Radiological Techniques and PET-CT in Treatment response evaluation in chemotherapy setting
Conventional Radiological Techniques and PET-CT in Treatment response evaluation in radiation oncology
Conventional Radiological Techniques and PET-CT in Treatment response evaluation in Immunotherapy settings
Treatment response evaluation of bone metastases using 18F-NaF
How to report PET-CT scans in post therapy scenarios: Do's and don'ts
PART II Atlas Articles: 18F-FDG  & Non FDG PET-CT in Treatment response evaluation in Head and neck cancer
18F-FDG  & Non FDG PET-CT in Treatment response evaluation in lung cancer
18F-FDG  & Non FDG PET-CT in Treatment response evaluation in neuro-oncology
18F-FDG  & Non FDG PET-CT in Treatment response evaluation in hepatobiliary cancer
18F-FDG  & Non FDG PET-CT in Treatment response evaluation in gastroesophageal cancer
18F-FDG & Non FDG PET-CT in Treatment response evaluation in Lymphoma and Non-hodgkins lymphoma
18F-FDG & Non FDG PET-CT in Treatment response evaluation in breast cancer
18F-FDG, 18F-Choline & 68Ga-PSMA PET-CT in Treatment response evaluation in prostate cancer
18F-FDG  & Non FDG PET-CT in Treatment response evaluation in gynaecological cancers
18F-FDG  & Non FDG PET-CT in Treatment response evaluation in colorectal cancer
18F-FDG  & Non FDG PET-CT in Treatment response evaluation in soft tissue sarcomas
FDG  & Non FDG PET-CT in Treatment response evaluation in malignant melanoma
18F-FDG & Non FDG PET-CT in Treatment response evaluation in myeloma
FDG PET-CT & 18F-NaF in Treatment response evaluation in bone metastases and bone tumours
18F-FDG  & Non FDG PET-CT in Assessment of treatment response in paediatric oncology
68Ga-DOTA PET-CT in Treatment response evaluation in NETs
18F-DOPA PET-CT in Treatment response evaluation
18F-FLT PET-CT in Treatment response evaluation
Brain PET-CT in Treatment response evaluation.</p>